Press Releases
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
August 01, 2019
Maastricht, The Netherlands, 1st August 2019 - Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high...
Read more
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
August 01, 2019
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals B.V. ("Modra") today announced the start of patient treatment in its Phase IIb clinical study evaluating the efficacy and tolerability of its lead candidate,...
Read more
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors
May 17, 2019
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and...
Read more
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
May 15, 2019
- Journal of Neuroscience publication demonstrates that antagonizing
miR-135a reduces seizures in chronic TLE model -
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019
April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019
April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief
April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019
March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial
March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
